The Company (as defined hereinafter) is furnishing this Executive Summary solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connection with the investment outlined herein. Prospective investors are urged to conduct an independent evaluation of the Company.
The document is based on data, estimates and forecasts that were prepared and/or approved by the Company appear to be reliable. The Executive Summary contains forward-looking statements involving known and unknown risks and uncertainties that may cause the Company\'92s actual results to be materially different from any future performance suggested herein. Ernst and Young Israel undertakes no responsibility to update or revise any data, estimates and forecasts, including forward-looking statements. 
 
The Company, and its respective affiliates, employees and representatives expressively disclaim any and all liability relating to or resulting from the use of the Executive Summary or such other information by a prospective investor or any of its affiliates or representatives. 
 
Ernst and Young Israel, by assisting the preparation of this Executive Summary, expressively disclaims any and all liability relating to or resulting from the use of the Executive Summary or such other information by a prospective investor or any of its affiliates or representatives. 
NEWS:
 
 MediTemp, Ltd. was founded in 2007 as an Israeli start up company. The Company has developed a unique cooling device technology designed to improve sperm quality in infertile men due to Varicoceles.

MediTemp is spearheaded by a strong management team with extensive experience and relevant knowledge to all aspects of MediTemp  commercialization. This includes long-standing meical experience in Urology and Varicoceles, and deep and comprehensive understanding of the healthcare system decision-making processes.
Dr. Dagan has more than twenty five years of experience as a BioTech executive, in management, operations, sales and finance with track record generating high multiple growth of BioTechnology public and private companies in the US and Israel.
Our device provides a new treatment option for infertility caused by Varicoceles, and has several advantages over the current alternatives: 

Improves semen quality within 3-6 months
Preserves fertility while in use Obviates the need for surgical treatment and/or IVF and associated complications Affordable Easy to use.
Dr. Nahhas holds B.Sc. in biology,  M.Sc. in immunology (Hebrew University, Jerusalem) &  D.Sc. in immunology from the Technion Institute of Technology, Israel  specializes in infertility and assisted reproductive procedures. He serves as the General Manager of S.H.I.F.A Ltd., a research and development company, manufacturing natural medicine to treat infertility. Scientific Advisor of the IVF Unit at Herzelia Medical Center for over 10 years.  Scientific Director of the IVF Unit, Department of Ob/Gyn at Rambam Medical Center, Haifa.

Israel    MediTemp Ltd

Phone  (972) 4-8644410

E-mail   nahhasf@netvision.net.il     

Address P.O.Box 45810 ,Haifa, 31457, Israel

+About

+Our Team

+Device


USA

Phone  +1(201) 670-9999

E-mail   jdagan@msobiz.com 

Address 36 Boulder Run, Oakland NJ, 07436, USA